Skip to main content

Table 3 Risk factors for 30-day mortality among patients with community-onset Klebsiella pneumoniae bloodstream infection in univariate analysis

From: Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea

 

No. of survivors

No. of non-survivors

OR (95% CI)

p

(n = 456)

(n = 97)

Age (year) (mean ±SD)

61.1 (±13.5)

63.3 (±12.1)

 

0.146

Male sex

287 (62.9)

61 (62.9)

1.00 (0.63-1.57)

0.992

Underlying disease

    

  Diabetes mellitus

128 (28.1)

17 (17.5)

0.55 (0.31-0.96)

0.032

  Chronic liver disease

94 (20.6)

29 (29.9)

1.64 (1.01-2.68)

0.046

  Biliary tract disease

77 (16.9)

8 (8.2)

0.44 (0.21-0.95)

0.032

  Chronic kidney disease

28 (6.1)

4 (4.1)

0.66 (0.26-1.92)

0.440

  Respiratory disease

34 (7.5)

5 (5.2)

0.68 (0.26-1.77)

0.421

  Solid tumor

173 (37.9)

65 (67.0)

3.32 (2.09-5.28)

<0.001

  Hematologic malignancy

16 (3.5)

11 (11.3)

3.52 (1.58-7.84)

0.003

  Solid organ transplantation

13 (2.9)

1 (1.0)

0.36 (0.05-2.75)

0.482

Charlson's WIC (≥3)

135 (29.6)

53 (54.6)

2.86 (1.83-4.48)

<0.001

Primary infection site

    

  Urinary tract

58 (12.7)

7 (7.2)

0.53 (0.24-1.22)

0.126

  Peritoneum

42 (9.2)

15 (15.5)

1.80 (0.96-3.40)

0.066

  Pancreatobiliary tract

163 (35.7)

21 (21.6)

0.50 (0.30-0.84)

0.007

  Liver

105 (23.0)

3 (3.1)

0.11 (0.03-0.35)

<0.001

  Lung

27 (5.9)

17 (17.5)

3.38 (1.76-6.48)

<0.001

  Skin and soft tissue

8 (1.8)

4 (4.1)

2.41 (0.71-8.17)

0.239

  Bone

5 (1.1)

1 (1.0)

0.94 (0.11-8.13)

1.000

  Central nervous system

1 (0.2)

0 (0)

0.82 (0.79-0.86)

1.000

  Othersa

3 (0.7)

1 (1.0)

1.57 (0.16-15.28)

0.539

  Unknown

45 (9.9)

28 (28.9)

3.71 (2.17-6.34)

<0.001

Metastatic infection

18 (3.9)

2 (2.1)

0.51 (0.12-2.25)

0.551

Endophthalmitis

8 (1.8)

0 (0)

0.82 (0.79-0.86)

0.362

Pitt bacteremia score (≥4)

46 (10.1)

46 (47.4)

8.04 (4.87-13.28)

<0.001

Shock at presentation

97 (21.3)

59 (60.8)

5.75 (3.61-9.15)

<0.001

Neutropenia at presentation

25 (5.5)

20 (20.6)

4.48 (2.37-8.46)

<0.001

Healthcare-associated infection

243 (53.3)

70 (72.2)

2.27 (1.41-3.68)

0.001

Polymicrobial infection

57 (12.5)

24 (24.7)

2.30 (1.34-3.94)

0.002

Antimicrobial resistance

    

  non-susceptible to CIP

32 (7.0)

9 (9.3)

1.36 (0.63-2.94)

0.440

  non-susceptible to ESC

29 (6.4)

8 (8.2)

1.32 (0.59-2.99)

0.499

Inappropriate empirical antimicrobial therapy

27 (5.9)

13 (13.4)

2.46 (1.22-4.96)

0.010

Inappropriate definitive antimicrobial therapyb

12/446 (2.7)

2/55 (3.6)

1.37 (0.30-6.26)

0.659

  1. Data indicate no. (%) of patients.
  2. WIC, weighted index of co-morbidity; CIP, ciprofloxacin; ESC, extended-spectrum cephalosporin; OR, odds ratio; CI, confidence interval.
  3. a Others were one appendicitis, one pericarditis and two periodontitis.
  4. b 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).